Omada Health is growing revenue rapidly with a perfect 4-quarter earnings beat streak, but the stock is technically overbought, has already exceeded its price target, and notable insider selling adds a cautionary signal.
Thesis pillars
- Strong Revenue Growth→Stable
- Overbought Late Cycle Risk↑Improving
- Notable Insider Selling↑Improving
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Jul 5, 2026, based on the 10-K filed Mar 6, 2026· older than 90 days
Omada Health, Inc. (OMDA) Stock Analysis
Inst Constrain edge
Healthcare · Health Information Services
Sell if holding. Engine safety override at $11.87: Risk below floor (1.6 < 2.5) triggers a hard block regardless of the otherwise-positive setup — overall score 6.3/10 and A.R:R 6.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Elevated put/call ratio: 1.44; Negative price momentum.
Omada Health, Inc., together with its subsidiary, Physera, Inc., provides a range of virtual care programs in the United States. The company offers cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address musculoskeletal... Read more
Sell if holding. Engine safety override at $11.87: Risk below floor (1.6 < 2.5) triggers a hard block regardless of the otherwise-positive setup — overall score 6.3/10 and A.R:R 6.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Elevated put/call ratio: 1.44; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Score 6.3/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, no SEC red flags, earnings proximity 102d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
Recent developments
No fresh coverage since Oct 29, 2026
Recent Developments — Omada Health, Inc.
Latest news
- NEWS OMDA Q3'26 Earnings: revenue estimate is 85.65M USD - TradingView — TradingView Oct 29, 2026 neutral
- NEWS Wells Fargo Maintains Omada Health(OMDA.US) With Hold Rating, Maintains Target Price $22 - Moomoo — Moomoo Oct 28, 2026 neutral
- NEWS Citizens reiterates Omada Health stock rating ahead of Q3 results By Investing.com - Investing.com Nigeria — Investing.com Nigeria Oct 27, 2026 neutral
- NEWS Omada Health (OMDA) Slips 0.16% to $18.95 as Shares Consolidate Between $18.00 Support and $19.90 Resistance - Fibonacci — https://www.dars.gov.et/ Oct 26, 2026 neutral
- NEWS Quantinno Capital Management LP Grows Stock Position in Omada Health, Inc. $OMDA - MarketBeat — MarketBeat Aug 19, 2026 neutral
Latest item Oct 29, 2026 · Generated 2026-11-22T11:32:08Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMCustomerlimited number of customers and channel partners10-K Item 1A: 'A substantial portion of our sales comes from or through a limited number of customers and channel partners that operate as resellers.'
- MEDIUMSupplierlimited number of third-party suppliers10-K Item 1A: 'We depend on a limited number of third-party suppliers for certain devices and other supplies that we deliver to members in connection with our programs'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Volatile — 9.8% daily ATR makes tight stops impractical. Position-size conservatively.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $11.87: Risk below floor (1.6 < 2.5) triggers a hard block regardless of the otherwise-positive setup — overall score 6.3/10 and A.R:R 6.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Elevated put/call ratio: 1.44; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $11.41. Score 6.3/10, moderate confidence.
Analyst target: $23.05 (+94.2% upside). Prior stop was $11.41. Stop-loss: $11.41.
Risk below floor (1.6 < 2.5).
Omada Health, Inc. trades at a P/E of 29.7 (forward 17.2). TrendMatrix value score: 7.0/10. Verdict: Sell.
18 analysts rate OMDA, with a consensus score of 4.0/5. 12 analysts publish price targets averaging $27.
What does Omada Health, Inc. do?Omada Health, Inc., together with its subsidiary, Physera, Inc., provides a range of virtual care programs in the...
Omada Health, Inc., together with its subsidiary, Physera, Inc., provides a range of virtual care programs in the United States. The company offers cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address musculoskeletal conditions; other support programs for members taking glucagon-like peptide-1 agonists in its cardiometabolic program; and weight management programs, as well as various behavioral health support programs. It also delivers virtual care. The company offers its programs for employers, health plans and systems, and pharmacy benefits managers through its direct sales force and channel partners. The company was incorporated in 2011 and is headquartered in South San Francisco, California.